Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.51 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.51 |
| ▸ | CBX7 | O95931 | 2/20 | 0.50 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.50 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.50 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.49 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005059 | 0.92 | KDM4E (0.68) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL13005710 | 0.92 | KDM4E (0.68) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3780589 | 0.92 | KDM4E (0.63) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3773620 | 0.92 | KDM4E (0.68) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3774024 | 0.92 | KDM4E (0.68) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3769500 | 0.92 | KDM4E (0.68) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3774221 | 0.92 | KDM4E (0.68) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL13005640 | 0.92 | KDM4E (0.68) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL13005094 | 0.91 | KDM4E (0.63) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL13005070 | 0.90 | KDM4E (0.65) | KDM4EALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | KDM4E 534/4885ALDH1A1 1210/4885GAA 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.